Skip to main content

Cepheid Acquires Swedish PCR Dx Kit Shop Sangtec for $27M in Cash

NEW YORK (GenomeWeb News) — Cepheid today said it has acquired PCR diagnostics company Sangtec Molecular Diagnostics from Altana Pharma for around $27 million in cash.   
Cepheid CEO John Bishop said the acquisition gives the company a “relatively complete line of products for managing infections of immunocompromised patients.”  
Bishop said the firm will also provide Cepheid with an established reagent-manufacturing base in Europe.
Cepheid said it will integrate Sangtec’s PCR diagnostic kits into its European and US in vitro product line, which will now offer assays for cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, hepatitis B virus, Varicella zoster virus, BK virus and Aspergillus.
Sangtec brings with it an R&D team with real-time PCR experience and an experienced manufacturing team as well, Bishop added.
Sangtec generated around $8 million in revenue last year and has 59 employees, Cepheid said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.